Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13191781 | 1.00 | CA2 (0.35) | CA2CA1CA9PI4KAPI4K2B | |
| SCHEMBL8815319 | 1.00 | CA2 (0.35) | CA2CA1CA9PI4KAPI4K2B | |
| SCHEMBL15660928 | 0.89 | CYP3A4 (0.32) | CA2CA1CA9PI4KAPI4K2B | |
| SCHEMBL15661135 | 0.89 | CYP3A4 (0.32) | CA2CA1CA9PI4KAPI4K2B | |
| SCHEMBL15657817 | 0.89 | CYP3A4 (0.32) | CA2CA1CA9PI4KAPI4K2B | |
| SCHEMBL8814583 | 0.88 | CA2 (0.33) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13194019 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL11965635 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 | |
| SCHEMBL10131262 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL1739854 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | CA2 320/4885CA1 865/4885CA9 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.